Aventis Pharma is committed to developing new respiratory therapies that will provide relief for allergy sufferers. Pediatric Use, CIU Indication Approved Aventis Pharma has also received two additional FDA clearances for fexofenadine. The nonsedating antihistamine has been approved for pediatric use in children ages 6 to 11 for seasonal allergy symptoms. Launch for both of these uses will occur later this year. Typical allergens that cause SAR include grass and tree pollens, molds and ragweed pollen.
Symptoms typically effect the nose, and itchy, watery eyes are also a commonly reported symptom.
Seasonal allergic rhinitis often remains undiagnosed and untreated because its symptoms are mistaken as a cold or the flu. Symptoms appear as raised areas of reddened skin that are itchy. CIU affects approximately 15 to 20 percent of the US population at some time in their lives. Aventis was launched in December 1999 through the merger of Hoechst AG and Rh ne-Poulenc S.A. Aventis Pharma AG is the pharmaceutical company of Aventis S.A. Aventis Pharma is dedicated to treating and preventing human disease through the discovery, development, manufacture and sale of innovative pharmaceutical products aimed at satisfying unmet medical needs. Aventis Pharma focuses on important therapeutic areas such as cardiology, oncology, infectious diseases, arthritis, allergies and respiratory disorders, diabetes and the central nervous system disorders.